Why Is Apellis Pharmaceuticals Stock Trading Lower Today?


Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a report by Citron Research casting doubts on the company's prospects and the safety of its recently approved treatment for Geographic Atrophy, Syfovre. 

The report anticipates an FDA warning letter and criticizes the lack of transparency surrounding the drug's approval process and side effect reports. 

Apellis is under scrutiny after alleged underreporting of retinal vasculitis cases associated with Syfovre use, a serious concern echoed by healthcare professionals despite the company's defense of its product's safety.

Cedric Francois, CEO of Apellis, faces skepticism over his disclosures to Wall Street, as the Citron report ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner